Lewis Lane
Psychiatry · Dana Point, CANPI 1053452573
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 63.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $528 and has fallen 66.9% since, to $174 in 2025.
Across 228 payments — averaging $10.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$354
- Takeda Pharmaceuticals U.S.A., Inc.$271
- Sunovion Pharmaceuticals Inc.$83
- E.r. Squibb & Sons, L.L.C.$45
- Lundbeck LLC$33
- plus $53 from 4 others
What the payments were for
- Food & beverage$2,290100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 135 | $1,450 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $271 |
| Sunovion Pharmaceuticals Inc. | 10 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Lundbeck LLC | 2 | $33 |
| Alkermes, Inc. | 1 | $13 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Tris Pharma Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$122
How this compares
$2,290 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 11 | $18,667 |
| RexultiBrexpiprazole | 12 | $17,756 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $15,172 |
| Adderall XrDextroamphetamine/Amphetamine | 36 | $9,569 |
| SaphrisAsenapine Maleate | 11 | $7,669 |
| AdderallDextroamphetamine/Amphetamine | 14 | $4,482 |
| Bupropion XlBupropion Hcl | 224 | $4,368 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 67 | $3,076 |
| Aripiprazole | 41 | $3,050 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 29 | $2,092 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $1,558 |
| Clonazepam | 168 | $1,108 |
| Lorazepam | 106 | $1,100 |
| Quetiapine Fumarate | 76 | $927 |
| Trazodone Hcl | 95 | $889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $354 | $18,66711 claims |
| AbbVieSaphris | $1,450 | $7,66911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $271 | $4,48214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Dana Point
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.